Eledon Pharmaceuticals Submits IND To FDA For Registrational Tegoprubart Study In Islet Cell Transplantation For Type 1 Diabetes; Reaffirms Q4 2026 Initiation Of Phase 3 LEGACY Kidney Transplant Trial

뉴스 본문을 불러오고 있어요.

Eledon Pharmaceuticals Submits IND To FDA For Registrational Tegoprubart Study In Islet Cell Transplantation For Type 1 Diabetes; Reaffirms Q4 2026 Initiation Of Phase 3 LEGACY Kidney Transplant Trial | 웨이프 WAPE

Eledon Pharmaceuticals Submits IND To FDA For Registrational Tegoprubart Study In Islet Cell Transplantation For Type 1 Diabetes; Reaffirms Q4 2026 Initiation Of Phase 3 LEGACY Kidney Transplant Trial

기사 요약

관련 종목

댓글 —